APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-angiogenic Ophthalmic Agent

Compare research editions
View pricing & licenses

Selected research

Industry Research

Anti-angiogenic Ophthalmic Agent Industry Research Report 2026

22 December 2025145 pages

Choose your research edition.

Industry ResearchAnti-angiogenic Ophthalmic Agent Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-angiogenic Ophthalmic Agent Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Anti-angiogenic Ophthalmic Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-angiogenic Ophthalmic Agent Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-angiogenic Ophthalmic Agent Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Anti-angiogenic Ophthalmic Agent market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Anti-angiogenic Ophthalmic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Anti-angiogenic Ophthalmic Agent is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Anti-angiogenic Ophthalmic Agent is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Anti-angiogenic Ophthalmic Agent include Sun Pharma, Johnson & Johnson, Novartis AG, Gilead Sciences, Inc., Pfizer, Daiichi Sankyo, Bayer AG, The Geuder Group, MORCHER GmbH and Shanghai Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Anti-angiogenic Ophthalmic Agent market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Anti-angiogenic Ophthalmic Agent Market by Company

Sun Pharma

Johnson & Johnson

Novartis AG

Gilead Sciences, Inc.

Pfizer

Daiichi Sankyo

Bayer AG

The Geuder Group, MORCHER GmbH

Shanghai Pharmaceuticals

Santen Pharmaceutical Co., Ltd.

Regeneron Pharmaceuticals, Inc.

Otsuka Pharmaceutical Co. Ltd

Novamedika

Medicom Health care

Implant ophthalmic products GmbH

Genentech, Inc.

Eyetech Inc.

ERC Labs

Becton, Dickinson and Company

Allergan plc

Anti-angiogenic Ophthalmic Agent Segment by Type

Diabetic Retinopathy

Myopic Choroidal Neovascularization

Macular Edema

Macular Degeneration

Anti-angiogenic Ophthalmic Agent Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Anti-angiogenic Ophthalmic Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-angiogenic Ophthalmic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-angiogenic Ophthalmic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-angiogenic Ophthalmic Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Anti-angiogenic Ophthalmic Agent manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Anti-angiogenic Ophthalmic Agent by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Anti-angiogenic Ophthalmic Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Anti-angiogenic Ophthalmic Agent Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Anti-angiogenic Ophthalmic Agent Sales (k units) of Manufacturers (2021-2026) Table 7. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Manufacturers (2021-2026) Table 8. Global Anti-angiogenic Ophthalmic Agent Revenue of Manufacturers (2021-2026) Table 9. Global Anti-angiogenic Ophthalmic Agent Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Anti-angiogenic Ophthalmic Agent Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Anti-angiogenic Ophthalmic Agent Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Anti-angiogenic Ophthalmic Agent, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Anti-angiogenic Ophthalmic Agent, Product Type & Application Table 14. Global Anti-angiogenic Ophthalmic Agent Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Anti-angiogenic Ophthalmic Agent by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sun Pharma Company Information Table 19. Sun Pharma Business Overview Table 20. Sun Pharma Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Sun Pharma Anti-angiogenic Ophthalmic Agent Product Portfolio Table 22. Sun Pharma Recent Developments Table 23. Johnson & Johnson Company Information Table 24. Johnson & Johnson Business Overview Table 25. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Portfolio Table 27. Johnson & Johnson Recent Developments Table 28. Novartis AG Company Information Table 29. Novartis AG Business Overview Table 30. Novartis AG Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Novartis AG Anti-angiogenic Ophthalmic Agent Product Portfolio Table 32. Novartis AG Recent Developments Table 33. Gilead Sciences, Inc. Company Information Table 34. Gilead Sciences, Inc. Business Overview Table 35. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 37. Gilead Sciences, Inc. Recent Developments Table 38. Pfizer Company Information Table 39. Pfizer Business Overview Table 40. Pfizer Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Pfizer Anti-angiogenic Ophthalmic Agent Product Portfolio Table 42. Pfizer Recent Developments Table 43. Daiichi Sankyo Company Information Table 44. Daiichi Sankyo Business Overview Table 45. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Portfolio Table 47. Daiichi Sankyo Recent Developments Table 48. Bayer AG Company Information Table 49. Bayer AG Business Overview Table 50. Bayer AG Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Bayer AG Anti-angiogenic Ophthalmic Agent Product Portfolio Table 52. Bayer AG Recent Developments Table 53. The Geuder Group, MORCHER GmbH Company Information Table 54. The Geuder Group, MORCHER GmbH Business Overview Table 55. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio Table 57. The Geuder Group, MORCHER GmbH Recent Developments Table 58. Shanghai Pharmaceuticals Company Information Table 59. Shanghai Pharmaceuticals Business Overview Table 60. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Portfolio Table 62. Shanghai Pharmaceuticals Recent Developments Table 63. Santen Pharmaceutical Co., Ltd. Company Information Table 64. Santen Pharmaceutical Co., Ltd. Business Overview Table 65. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 67. Santen Pharmaceutical Co., Ltd. Recent Developments Table 68. Regeneron Pharmaceuticals, Inc. Company Information Table 69. Regeneron Pharmaceuticals, Inc. Business Overview Table 70. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 72. Regeneron Pharmaceuticals, Inc. Recent Developments Table 73. Otsuka Pharmaceutical Co. Ltd Company Information Table 74. Otsuka Pharmaceutical Co. Ltd Business Overview Table 75. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Portfolio Table 77. Otsuka Pharmaceutical Co. Ltd Recent Developments Table 78. Novamedika Company Information Table 79. Novamedika Business Overview Table 80. Novamedika Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Novamedika Anti-angiogenic Ophthalmic Agent Product Portfolio Table 82. Novamedika Recent Developments Table 83. Medicom Health care Company Information Table 84. Medicom Health care Business Overview Table 85. Medicom Health care Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Medicom Health care Anti-angiogenic Ophthalmic Agent Product Portfolio Table 87. Medicom Health care Recent Developments Table 88. Implant ophthalmic products GmbH Company Information Table 89. Implant ophthalmic products GmbH Business Overview Table 90. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio Table 92. Implant ophthalmic products GmbH Recent Developments Table 93. Genentech, Inc. Company Information Table 94. Genentech, Inc. Business Overview Table 95. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 97. Genentech, Inc. Recent Developments Table 98. Eyetech Inc. Company Information Table 99. Eyetech Inc. Business Overview Table 100. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 102. Eyetech Inc. Recent Developments Table 103. ERC Labs Company Information Table 104. ERC Labs Business Overview Table 105. ERC Labs Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. ERC Labs Anti-angiogenic Ophthalmic Agent Product Portfolio Table 107. ERC Labs Recent Developments Table 108. Becton, Dickinson and Company Company Information Table 109. Becton, Dickinson and Company Business Overview Table 110. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Portfolio Table 112. Becton, Dickinson and Company Recent Developments Table 113. Allergan plc Company Information Table 114. Allergan plc Business Overview Table 115. Allergan plc Anti-angiogenic Ophthalmic Agent Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Allergan plc Anti-angiogenic Ophthalmic Agent Product Portfolio Table 117. Allergan plc Recent Developments Table 118. Global Anti-angiogenic Ophthalmic Agent Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2021-2026) & (k units) Table 120. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2021-2026) Table 121. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2027-2032) & (k units) Table 122. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2027-2032) Table 123. Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2021-2026) & (US$ Million) Table 124. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2021-2026) Table 125. Global Anti-angiogenic Ophthalmic Agent Revenue by Region (2027-2032) & (US$ Million) Table 126. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Region (2027-2032) Table 127. North America Anti-angiogenic Ophthalmic Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 129. North America Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units) Table 130. North America Anti-angiogenic Ophthalmic Agent Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Anti-angiogenic Ophthalmic Agent Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe Anti-angiogenic Ophthalmic Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 134. Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units) Table 135. Europe Anti-angiogenic Ophthalmic Agent Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Anti-angiogenic Ophthalmic Agent Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific Anti-angiogenic Ophthalmic Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 139. Asia Pacific Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units) Table 140. Asia Pacific Anti-angiogenic Ophthalmic Agent Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific Anti-angiogenic Ophthalmic Agent Revenue by Country (2027-2032) & (US$ Million) Table 142. South America Anti-angiogenic Ophthalmic Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 144. South America Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units) Table 145. South America Anti-angiogenic Ophthalmic Agent Revenue by Country (2021-2026) & (US$ Million) Table 146. South America Anti-angiogenic Ophthalmic Agent Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Anti-angiogenic Ophthalmic Agent Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 149. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units) Table 150. Middle East and Africa Anti-angiogenic Ophthalmic Agent Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Anti-angiogenic Ophthalmic Agent Revenue by Country (2027-2032) & (US$ Million) Table 152. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2026) & (k units) Table 153. Global Anti-angiogenic Ophthalmic Agent Sales by Type (2027-2032) & (k units) Table 154. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2021-2026) Table 155. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2027-2032) Table 156. Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2026) & (US$ Million) Table 157. Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2027-2032) & (US$ Million) Table 158. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2021-2026) Table 159. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2027-2032) Table 160. Global Anti-angiogenic Ophthalmic Agent Price by Type (2021-2026) & (US$/unit) Table 161. Global Anti-angiogenic Ophthalmic Agent Price by Type (2027-2032) & (US$/unit) Table 162. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2026) & (k units) Table 163. Global Anti-angiogenic Ophthalmic Agent Sales by Application (2027-2032) & (k units) Table 164. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2021-2026) Table 165. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2027-2032) Table 166. Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2026) & (US$ Million) Table 167. Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2027-2032) & (US$ Million) Table 168. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2021-2026) Table 169. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2027-2032) Table 170. Global Anti-angiogenic Ophthalmic Agent Price by Application (2021-2026) & (US$/unit) Table 171. Global Anti-angiogenic Ophthalmic Agent Price by Application (2027-2032) & (US$/unit) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Anti-angiogenic Ophthalmic Agent Distributors List Table 175. Anti-angiogenic Ophthalmic Agent Customers List Table 176. Anti-angiogenic Ophthalmic Agent Industry Trends Table 177. Anti-angiogenic Ophthalmic Agent Industry Drivers Table 178. Anti-angiogenic Ophthalmic Agent Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Anti-angiogenic Ophthalmic Agent Product Image Figure 5. Global Anti-angiogenic Ophthalmic Agent Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Anti-angiogenic Ophthalmic Agent Market Size (2021-2032) & (US$ Million) Figure 7. Global Anti-angiogenic Ophthalmic Agent Sales (2021-2032) & (k units) Figure 8. Global Anti-angiogenic Ophthalmic Agent Average Price (US$/unit) & (2021-2032) Figure 9. Diabetic Retinopathy Product Image Figure 10. Myopic Choroidal Neovascularization Product Image Figure 11. Macular Edema Product Image Figure 12. Macular Degeneration Product Image Figure 13. Hospital Pharmacies Product Image Figure 14. Online Pharmacies Product Image Figure 15. Retail Pharmacies Product Image Figure 16. Global Anti-angiogenic Ophthalmic Agent Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Anti-angiogenic Ophthalmic Agent, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Anti-angiogenic Ophthalmic Agent Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Anti-angiogenic Ophthalmic Agent Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Anti-angiogenic Ophthalmic Agent Sales by Region in 2025 Figure 22. Global Anti-angiogenic Ophthalmic Agent Revenue by Region in 2025 Figure 23. North America Anti-angiogenic Ophthalmic Agent Market Size by Country in 2025 Figure 24. North America Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2032) Figure 25. North America Anti-angiogenic Ophthalmic Agent Revenue Market Share by Country (2021-2032) Figure 26. United States Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Anti-angiogenic Ophthalmic Agent Market Size by Country in 2025 Figure 30. Europe Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2032) Figure 31. Europe Anti-angiogenic Ophthalmic Agent Revenue Market Share by Country (2021-2032) Figure 32. Germany Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Anti-angiogenic Ophthalmic Agent Market Size by Country in 2025 Figure 43. Asia Pacific Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Anti-angiogenic Ophthalmic Agent Revenue Market Share by Country (2021-2032) Figure 45. China Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Anti-angiogenic Ophthalmic Agent Market Size by Country in 2025 Figure 54. South America Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2032) Figure 55. South America Anti-angiogenic Ophthalmic Agent Revenue Market Share by Country (2021-2032) Figure 56. Brazil Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Size by Country in 2025 Figure 60. Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Anti-angiogenic Ophthalmic Agent Revenue Market Share by Country (2021-2032) Figure 62. Egypt Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Anti-angiogenic Ophthalmic Agent Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2021-2032) Figure 68. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2021-2032) Figure 69. Global Anti-angiogenic Ophthalmic Agent Price (US$/unit) by Type (2021-2032) Figure 70. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2021-2032) Figure 71. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2021-2032) Figure 72. Global Anti-angiogenic Ophthalmic Agent Price (US$/unit) by Application (2021-2032) Figure 73. Anti-angiogenic Ophthalmic Agent Value Chain Figure 74. Anti-angiogenic Ophthalmic Agent Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Anti-angiogenic Ophthalmic Agent Industry Opportunities and Challenges

Scope & coverage.

Types
  • Diabetic Retinopathy
  • Myopic Choroidal Neovascularization
  • Macular Edema
  • Macular Degeneration
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Sun Pharma
  • Johnson & Johnson
  • Novartis AG
  • Gilead Sciences, Inc.
  • Pfizer
  • Daiichi Sankyo
  • Bayer AG
  • The Geuder Group, MORCHER GmbH
  • Shanghai Pharmaceuticals
  • Santen Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co. Ltd
  • Novamedika
  • Medicom Health care
  • Implant ophthalmic products GmbH
  • Genentech, Inc.
  • Eyetech Inc.
  • ERC Labs
  • Becton, Dickinson and Company
  • Allergan plc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Anti-angiogenic Ophthalmic Agent Market Size (2021-2032)
  4. 2.2.2 Global Anti-angiogenic Ophthalmic Agent Sales (2021-2032)
  5. 2.2.3 Global Anti-angiogenic Ophthalmic Agent Market Average Price (2021-2032)
  6. 2.3 Anti-angiogenic Ophthalmic Agent by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Diabetic Retinopathy
  9. 2.3.3 Myopic Choroidal Neovascularization
  10. 2.3.4 Macular Edema
  11. 2.3.5 Macular Degeneration
  12. 2.4 Anti-angiogenic Ophthalmic Agent by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Hospital Pharmacies
  15. 2.4.3 Online Pharmacies
  16. 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Anti-angiogenic Ophthalmic Agent Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Anti-angiogenic Ophthalmic Agent Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Anti-angiogenic Ophthalmic Agent Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Anti-angiogenic Ophthalmic Agent Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Anti-angiogenic Ophthalmic Agent Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Anti-angiogenic Ophthalmic Agent, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Anti-angiogenic Ophthalmic Agent, Product Type & Application
  8. 3.8 Global Manufacturers of Anti-angiogenic Ophthalmic Agent, Established Date
  9. 3.9 Global Anti-angiogenic Ophthalmic Agent Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sun Pharma
  2. 4.1.1 Sun Pharma Company Information
  3. 4.1.2 Sun Pharma Business Overview
  4. 4.1.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sun Pharma Anti-angiogenic Ophthalmic Agent Product Portfolio
  6. 4.1.5 Sun Pharma Recent Developments
  7. 4.2 Johnson & Johnson
  8. 4.2.1 Johnson & Johnson Company Information
  9. 4.2.2 Johnson & Johnson Business Overview
  10. 4.2.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Portfolio
  12. 4.2.5 Johnson & Johnson Recent Developments
  13. 4.3 Novartis AG
  14. 4.3.1 Novartis AG Company Information
  15. 4.3.2 Novartis AG Business Overview
  16. 4.3.3 Novartis AG Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis AG Anti-angiogenic Ophthalmic Agent Product Portfolio
  18. 4.3.5 Novartis AG Recent Developments
  19. 4.4 Gilead Sciences, Inc.
  20. 4.4.1 Gilead Sciences, Inc. Company Information
  21. 4.4.2 Gilead Sciences, Inc. Business Overview
  22. 4.4.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  24. 4.4.5 Gilead Sciences, Inc. Recent Developments
  25. 4.5 Pfizer
  26. 4.5.1 Pfizer Company Information
  27. 4.5.2 Pfizer Business Overview
  28. 4.5.3 Pfizer Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Pfizer Anti-angiogenic Ophthalmic Agent Product Portfolio
  30. 4.5.5 Pfizer Recent Developments
  31. 4.6 Daiichi Sankyo
  32. 4.6.1 Daiichi Sankyo Company Information
  33. 4.6.2 Daiichi Sankyo Business Overview
  34. 4.6.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Portfolio
  36. 4.6.5 Daiichi Sankyo Recent Developments
  37. 4.7 Bayer AG
  38. 4.7.1 Bayer AG Company Information
  39. 4.7.2 Bayer AG Business Overview
  40. 4.7.3 Bayer AG Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Bayer AG Anti-angiogenic Ophthalmic Agent Product Portfolio
  42. 4.7.5 Bayer AG Recent Developments
  43. 4.8 The Geuder Group, MORCHER GmbH
  44. 4.8.1 The Geuder Group, MORCHER GmbH Company Information
  45. 4.8.2 The Geuder Group, MORCHER GmbH Business Overview
  46. 4.8.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
  48. 4.8.5 The Geuder Group, MORCHER GmbH Recent Developments
  49. 4.9 Shanghai Pharmaceuticals
  50. 4.9.1 Shanghai Pharmaceuticals Company Information
  51. 4.9.2 Shanghai Pharmaceuticals Business Overview
  52. 4.9.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Portfolio
  54. 4.9.5 Shanghai Pharmaceuticals Recent Developments
  55. 4.10 Santen Pharmaceutical Co., Ltd.
  56. 4.10.1 Santen Pharmaceutical Co., Ltd. Company Information
  57. 4.10.2 Santen Pharmaceutical Co., Ltd. Business Overview
  58. 4.10.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Portfolio
  60. 4.10.5 Santen Pharmaceutical Co., Ltd. Recent Developments
  61. 4.11 Regeneron Pharmaceuticals, Inc.
  62. 4.11.1 Regeneron Pharmaceuticals, Inc. Company Information
  63. 4.11.2 Regeneron Pharmaceuticals, Inc. Business Overview
  64. 4.11.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  66. 4.11.5 Regeneron Pharmaceuticals, Inc. Recent Developments
  67. 4.12 Otsuka Pharmaceutical Co. Ltd
  68. 4.12.1 Otsuka Pharmaceutical Co. Ltd Company Information
  69. 4.12.2 Otsuka Pharmaceutical Co. Ltd Business Overview
  70. 4.12.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Portfolio
  72. 4.12.5 Otsuka Pharmaceutical Co. Ltd Recent Developments
  73. 4.13 Novamedika
  74. 4.13.1 Novamedika Company Information
  75. 4.13.2 Novamedika Business Overview
  76. 4.13.3 Novamedika Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Novamedika Anti-angiogenic Ophthalmic Agent Product Portfolio
  78. 4.13.5 Novamedika Recent Developments
  79. 4.14 Medicom Health care
  80. 4.14.1 Medicom Health care Company Information
  81. 4.14.2 Medicom Health care Business Overview
  82. 4.14.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Medicom Health care Anti-angiogenic Ophthalmic Agent Product Portfolio
  84. 4.14.5 Medicom Health care Recent Developments
  85. 4.15 Implant ophthalmic products GmbH
  86. 4.15.1 Implant ophthalmic products GmbH Company Information
  87. 4.15.2 Implant ophthalmic products GmbH Business Overview
  88. 4.15.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
  90. 4.15.5 Implant ophthalmic products GmbH Recent Developments
  91. 4.16 Genentech, Inc.
  92. 4.16.1 Genentech, Inc. Company Information
  93. 4.16.2 Genentech, Inc. Business Overview
  94. 4.16.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  96. 4.16.5 Genentech, Inc. Recent Developments
  97. 4.17 Eyetech Inc.
  98. 4.17.1 Eyetech Inc. Company Information
  99. 4.17.2 Eyetech Inc. Business Overview
  100. 4.17.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  102. 4.17.5 Eyetech Inc. Recent Developments
  103. 4.18 ERC Labs
  104. 4.18.1 ERC Labs Company Information
  105. 4.18.2 ERC Labs Business Overview
  106. 4.18.3 ERC Labs Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 ERC Labs Anti-angiogenic Ophthalmic Agent Product Portfolio
  108. 4.18.5 ERC Labs Recent Developments
  109. 4.19 Becton, Dickinson and Company
  110. 4.19.1 Becton, Dickinson and Company Company Information
  111. 4.19.2 Becton, Dickinson and Company Business Overview
  112. 4.19.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Portfolio
  114. 4.19.5 Becton, Dickinson and Company Recent Developments
  115. 4.20 Allergan plc
  116. 4.20.1 Allergan plc Company Information
  117. 4.20.2 Allergan plc Business Overview
  118. 4.20.3 Allergan plc Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Allergan plc Anti-angiogenic Ophthalmic Agent Product Portfolio
  120. 4.20.5 Allergan plc Recent Developments
5 Global Anti-angiogenic Ophthalmic Agent Market Scenario by Region
  1. 5.1 Global Anti-angiogenic Ophthalmic Agent Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2021-2032
  3. 5.2.1 Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2021-2026
  4. 5.2.2 Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2027-2032
  5. 5.3 Global Anti-angiogenic Ophthalmic Agent Revenue by Region: 2021-2032
  6. 5.3.1 Global Anti-angiogenic Ophthalmic Agent Revenue by Region: 2021-2026
  7. 5.3.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Region: 2027-2032
  8. 5.4 North America Anti-angiogenic Ophthalmic Agent Market Facts & Figures by Country
  9. 5.4.1 North America Anti-angiogenic Ophthalmic Agent Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2032)
  11. 5.4.3 North America Anti-angiogenic Ophthalmic Agent Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Anti-angiogenic Ophthalmic Agent Market Facts & Figures by Country
  16. 5.5.1 Europe Anti-angiogenic Ophthalmic Agent Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2032)
  18. 5.5.3 Europe Anti-angiogenic Ophthalmic Agent Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Anti-angiogenic Ophthalmic Agent Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Anti-angiogenic Ophthalmic Agent Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Anti-angiogenic Ophthalmic Agent Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Anti-angiogenic Ophthalmic Agent Market Facts & Figures by Country
  41. 5.7.1 South America Anti-angiogenic Ophthalmic Agent Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2032)
  43. 5.7.3 South America Anti-angiogenic Ophthalmic Agent Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Anti-angiogenic Ophthalmic Agent Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Anti-angiogenic Ophthalmic Agent Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2032)
  2. 6.1.1 Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Type (2021-2032)
  4. 6.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Type (2021-2032)
  5. 6.2.1 Global Anti-angiogenic Ophthalmic Agent Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Anti-angiogenic Ophthalmic Agent Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2032)
  2. 7.1.1 Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Application (2021-2032)
  4. 7.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Application (2021-2032)
  5. 7.2.1 Global Anti-angiogenic Ophthalmic Agent Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Anti-angiogenic Ophthalmic Agent Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Anti-angiogenic Ophthalmic Agent Value Chain Analysis
  2. 8.1.1 Anti-angiogenic Ophthalmic Agent Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Anti-angiogenic Ophthalmic Agent Production Mode & Process
  5. 8.2 Anti-angiogenic Ophthalmic Agent Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Anti-angiogenic Ophthalmic Agent Distributors
  8. 8.2.3 Anti-angiogenic Ophthalmic Agent Customers
9 Global Anti-angiogenic Ophthalmic Agent Analyzing Market Dynamics
  1. 9.1 Anti-angiogenic Ophthalmic Agent Industry Trends
  2. 9.2 Anti-angiogenic Ophthalmic Agent Industry Drivers
  3. 9.3 Anti-angiogenic Ophthalmic Agent Industry Opportunities and Challenges
  4. 9.4 Anti-angiogenic Ophthalmic Agent Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst